Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 106.00

+0.8%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	10/17/2014 1:51:00 PM
	of 3202

Talked about panabinostat, and results showing recovery of marrow. Now there's a new investigator-sponsored trial (MEI Pharma as collaborator) using pracinostat..... clinicaltrials.gov >> The clinical progress that has been made by hydroxamic acid derivatives as HDAC inhibitors is of particular interest because they are usually considered as non-druggable and are down-prioritized in lead identification campaigns attributing to their poor physicochemical and ADME properties. SB939 (Pracinostat) is a potent HDACi that was discovered and developed at S*BIO (Wang et al., 2011; Novotny-Diermayr et al, 2011) to overcome some of the ADME and PK/PD (Pharmacokinetic/Pharmacodynamic) limitations of the current HDACi. << cdn.intechopen.com Nice to have other companies working to solidify your market! And it looks like they'll be paying for the rux.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next